Racial and Socioeconomic Disparities in Presentation and Outcomes of Well-Differentiated Thyroid Cancer

被引:119
|
作者
Harari, Avital [1 ]
Li, Ning [2 ]
Yeh, Michael W. [1 ]
机构
[1] Univ Calif Los Angeles, Sect Endocrine Surg, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA
来源
关键词
UNITED-STATES; HEALTH DISPARITIES; AFRICAN-AMERICANS; BREAST-CANCER; INCREASING INCIDENCE; ETHNIC-GROUPS; SURVIVAL; WOMEN; RISK; CARE;
D O I
10.1210/jc.2013-2781
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Racial/ethnic minorities suffer disproportionate morbidity and mortality from chronic diseases. Objective: Our objective was to assess racial and socioeconomic status (SES) disparities in well-differentiated thyroid cancer (WDTC) patients. Design and Participants: We conducted a retrospective cohort study on 25 945 patients with WDTC (1999-2008) from the California Cancer Registry (57% white, 4% black, 24% Hispanic, and 15% Asian-Pacific Islander [API]). Main Outcomes: We evaluated effect of race and SES variables on stage of cancer presentation and overall/disease-specific survival. Results: Significant differences in stage of presentation between all racial groups were found (P < .001), with minority groups presenting with a higher percentage of metastatic disease as compared with white patients (black, odds ratio [OR] = 1.36 with confidence interval [CI] 1.01-1.84; Hispanic, OR = 1.89 [CI, 1.62-2.21], API, OR = 1.82 [CI, 1.54-2.15]). Hispanic (OR = 1.59, [CI, 1.48-1.72]) and API (OR = 1.32 [1.22-1.44]) patients also presented with higher odds of regional disease. Patients with the lowest SES presented with metastatic disease more often than those with the highest SES (OR = 1.45 [CI, 1.16-1.82]). Those that were poor/uninsured and/or with Medicaid insurance had higher odds of presenting with metastatic disease as compared with those with private insurance (OR = 2.41, [CI, 2.10-2.77]). Unadjusted overall survival rates were higher among API and Hispanic patients and lower among black patients (P < .001 vs white patients). Adjusted overall survival also showed a survival disadvantage for black patients (hazard ratio = 1.4, [CI, 1.10-1.73]) and survival advantage for API patients (hazard ratio = 0.83, [CI, 0.71-0.97]). In disease-specific survival analyses, when only those patients with metastatic disease were analyzed separately, black patients again had the lowest survival rates, and Hispanic/API patients had the highest survival rates (P < .04). Conclusion: Black patients and those with low SES have worse outcomes for thyroid cancer. API and Hispanic patients may have a protective effect on survival despite presenting with more advanced disease.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 50 条
  • [41] Rapid thyroid nodule growth is not a marker for well-differentiated thyroid cancer
    Falch, Claudius
    Axt, Steffen
    Scuffi, Bettina
    Koenigsrainer, Alfred
    Kirschniak, Andreas
    Muller, Sven
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2015, 13
  • [42] Pathologic Characteristics and Surgical Outcomes of Pediatric Versus Adult Well-Differentiated Thyroid Cancer
    Gilja, Shivee
    Kumar, Arvind
    Londino, Aldo V.
    Kirke, Diana N.
    Roof, Scott A.
    van Gerwen, Maaike
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2024, 171 (06) : 1682 - 1689
  • [43] Rapid thyroid nodule growth is not a marker for well-differentiated thyroid cancer
    Claudius Falch
    Steffen Axt
    Bettina Scuffi
    Alfred Koenigsrainer
    Andreas Kirschniak
    Sven Muller
    World Journal of Surgical Oncology, 13
  • [44] Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer
    Singer, PA
    Cooper, DS
    Daniels, GH
    Ladenson, PW
    Greenspan, FS
    Levy, EG
    Braverman, LE
    Clark, OH
    McDougall, IR
    Ain, KV
    Dorfman, SG
    ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (19) : 2165 - 2172
  • [45] Socioeconomic Factors are Associated with Disparities in the Management of Differentiated Thyroid Cancer
    Liu, J. Y.
    Patel, S. G.
    Weber, C.
    Ko, C. Y.
    Sharma, J.
    Yang, A. D.
    Saunders, N. D.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S27 - S27
  • [46] Recurrent well-differentiated thyroid carcinoma
    Magarey, Matthew J. R.
    Freeman, Jeremy L.
    ORAL ONCOLOGY, 2013, 49 (07) : 689 - 694
  • [47] Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer
    Lin, Shu-Fu
    Lin, Jen-Der
    Yeh, Chun-Nan
    Huang, Yu-Tung
    Chou, Ting-Chao
    Wong, Richard J.
    ENDOCRINE-RELATED CANCER, 2019, 26 (08) : 727 - 738
  • [48] Surgical Decision Making in the Management of Well-Differentiated Thyroid Cancer
    Chernichenko N.
    Shaha A.R.
    Indian Journal of Surgical Oncology, 2012, 3 (3) : 161 - 165
  • [49] PREDICTORS OF LEVEL V METASTASIS IN WELL-DIFFERENTIATED THYROID CANCER
    Kupferman, Michael E.
    Weinstock, Y. Etan
    Santillan, Alfredo A.
    Mishra, Anupam
    Roberts, Dianna
    Clayman, Gary L.
    Weber, Randal S.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2008, 30 (11): : 1469 - 1474
  • [50] Risk Factors for Recurrence in Filipinos with Well-Differentiated Thyroid Cancer
    Lo, Tom Edward Ngo
    Canto, Abigail Uy
    Maningat, Patricia Deanna D.
    ENDOCRINOLOGY AND METABOLISM, 2015, 30 (04) : 543 - 550